Treating Rheumatoid Arthritis with disease specific anti-CD44
monoclonal antibodies.
Overview
The CD44 molecule and its splice variants provide new
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
opportunities for the discovery of specific therapies for cancer
and inflammatory diseases.
MaimoniDex RA's proprietary monoclonal antibodies aim at
eradicating or markedly reducing the destructive inflammatory
activity in Rheumatoid Arthritis.
These antibodies specifically target a CD44 splice variant,
unique to inflammatory synovial cells expressed in Rheumatoid
Arthritis patients, but leave cells engaged in normal biological
and immunological functions undamaged.
A successful accomplishment of this project should provide the
first specific drug for the treatment of Rheumatoid Arthritis.
Alternative CD44 mRNA splicing in inflammatory synovial fluid
cells of Rheumatoid Arthritis patients leads to the production of
a modified disease-specific protein, which can be targeted
therapeutically to modify the function of these cells.
The company is developing monoclonal antibodies that specifically
target this modified CD44 protein without effecting normal immune
system cells expressing the normal form of CD44.
